Last reviewed · How we verify

Nutritional Specialties, Inc. — Portfolio Competitive Intelligence Brief

Nutritional Specialties, Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Digestive Enzyme Liquescence PAPAIN marketed Non-Standardized Food Allergenic Extract [EPC] Pain
Pancreas Liquescence CHROMIUM marketed Standardized Chemical Allergen [EPC] Metabolic

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 2 shared drug classes
  2. University of Guadalajara · 2 shared drug classes
  3. Deseret Biologicals, Inc. · 1 shared drug class
  4. Dr. Laurence Klotz · 1 shared drug class
  5. Energique, Inc. · 1 shared drug class
  6. Forces of Nature · 1 shared drug class
  7. Historical Remedies LLP · 1 shared drug class
  8. Donat R. Spahn · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nutritional Specialties, Inc.:

Cite this brief

Drug Landscape (2026). Nutritional Specialties, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nutritional-specialties-inc. Accessed 2026-06-10.

Related